The JCA Is Coming: Evolving Perspectives From EU Stakeholders

Author(s)

Counihan J1, Bryan A2, Wu K3, Ismailoglu I4
1Trinity Life Sciences, Colorado Springs, CO, USA, 2Trinity Life Sciences, Brooklyn, NY, USA, 3Trinity Life Sciences, New York City, NY, USA, 4Trinity Life Sciences, Minneapolis, MN, USA

OBJECTIVES: The Joint Clinical Assessment (JCA) will become mandatory in Europe next January. Previous research has aimed to evaluate the potential impact of widespread European adoption of the JCA as a new requirement for Health Technology Assessments. As the official implementation approaches, further research is required to understand the state of implementation and current/evolving stakeholder perceptions.

METHODS: This study presents the results of primary research from N=8 ex-payer stakeholders across Germany, France, Italy, and Spain to provide current perceptions of the JCA and potential future impact of widespread European adoption. We also utilize retrospective interview results to show how payers' perceptions/knowledge of JCA implementation evolved over the past year.

RESULTS: Retrospective research found that most payers have high confidence in the parameters and evaluation criteria within the JCA. However, countries were still planning to conduct their own supplemental clinical assessments, which creates redundancies. Italian and Spanish payers were working to implement a cost-effectiveness evaluation upon JCA implementation, but the level of integration remains unclear. German payers reported seamless integration of the JCA into their current system given alignment of local priorities with the JCA parameters, whereas French payers experienced some adoption inertia as they were still thinking through how best to integrate the JCA into their own evaluation processes.

Despite the confidence in the parameters and evaluation criteria within the JCA, many hurdles and uncertainties regarding implementation remain. This study will provide updated insights into the implementation and impact of the JCA plus fill any gaps from last year’s research.

CONCLUSIONS: Overall, this research suggests that while the JCA has been well-received by payers across Europe, there is still work to be done to ensure efficient implementation. The study highlights the need for continued research into the state of implementation and evolution of stakeholder perceptions of the JCA.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA364

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×